Cellectar Biosciences (Warrant)
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CLRBZ and buy or sell other stocks, ETFs, and their options commission-free!About CLRBZ
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination.
CEOJames V. Caruso
CEOJames V. Caruso
Employees—
Employees—
HeadquartersFlorham Park, New Jersey
HeadquartersFlorham Park, New Jersey
Founded1996
Founded1996
Employees—
Employees—
CLRBZ Key Statistics
Market cap—
Market cap—
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume—
Average volume—
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high—
52 Week high—
52 Week low—
52 Week low—
CLRBZ News
TipRanks 4h
Cellectar Biosciences assumed with a Buy at LadenburgLadenburg assumed coverage of Cellectar Biosciences (CLRB) with a Buy rating and $10 price target Published first on TheFly – the ultimate source for real-time...
TipRanks 19h
Cellectar Biosciences Signals Pivotal Turn in Earnings CallCellectar Biosciences Inc ((CLRB)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level da...
The Motley Fool 1d
Cellectar Q1 2026 Earnings TranscriptImage source: The Motley Fool. Thursday, May 14, 2026 at 8:30 a.m. ET Call participants President and CEO — James Caruso Chief Financial Officer — Chad Kolean...
More CLRBZ News
TipRanks 1d
Cellectar Biosciences reports Q1 EPS ($1.33), consensus ($1.88)“The first part of 2026 was a pivotal period for Cellectar as we executed across our pipeline and capital strategies to position the company for value creation,...